5-substituted indazoles as kinase inhibitors
US8648069B2 · kind B2 · utility
41Cited by
1References
7Claims
0Family size
Assignee
Inventors
- Irini Akritopoulou-Zanze
- Brian D. Wakefield
- Helmut Mack
- Sean Colm Turner
- Alan F. Gasiecki
- Vijaya J. Gracias
- Kathy Sarris
- Douglas M. Kalvin
- Melissa J. Michmerhuizen
- Qi Shuai
- Jyoti R. Patel
- Margaretha H.M. Bakker
- Nicole Teusch
- Eric F. Johnson
- Peter J. Kovar
- Stevan W. Djuric
- Andrew J. Long
- Anil Vasudevan
- Dawn M. George
- Lu Wang
- Biqin C. Li
- N. St. John Moore
- Adrian D. Hobson
- Keith W. Woods
- Julie M. Miyashiro
- Steven L. Swann, Jr.
- Thomas D. Penning
Key dates
| Filing date | Dec 4, 2008 |
| Grant date | Feb 11, 2014 |
| Priority date | — |
| Expiry date | Dec 7, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts,wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.